Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

InnoCyte GmbH. (1/21/15). "Press Release: Biomaterials Innovation Network Biomat-IN Supports Partnership of InnoCyte and PharmaCell. Innovative solutions for bioproduction". Stuttgart & Maastricht.

Organisations Organisation InnoCyte GmbH
  Organisation 2 PharmaCell B.V.
  Group Lonza (Group)
Products Product Split.It device
  Product 2 cell therapy
Index terms Index term InnoCyte–PharmaCell: cell analysis technology, 201501– collab within Biomat-IN network to scientifically support cell passage device
  Index term 2 Biomat-IN project–EU (govt): grant, 201103–201402 support €1.24m from ERDF under Interreg IVB North West Europe
Persons Person Brunswiek, Soenke (PharmCell 201501 Director Business Development)
  Person 2 Eichenberg, Klaus (BioRegio STERN 200601 Managing Director)

The Biomaterials Innovation Network Biomat-IN supports the cooperation of InnoCyte and PharmaCell on the future market of the bioproduction of cells and tissue for medical research and therapy. At first, all is to be focused on InnoCyte's product, which is the first benchtop device worldwide for cell passage.

Stuttgart / Maastricht, January 21, 2015: InnoCyte and PharmaCell announced today that both companies are working together as partners to scientifically support InnoCyte's product, which is the first benchtop device worldwide for cell passage. Both companies will also investigate the options for further developing the technology platform of InnoCyte regarding GMP bioproduction and cell therapy. This cooperation has been developed in the scope of the Biomaterials Innovation Network Biomat-IN and is sponsored.

In reaction to the market requirements, InnoCyte follows a flexible, modular strategy: Benchtop devices are to close the gap between labor-intensive and error-prone manual laboratory tasks and the expensive, highly complex robot systems. This way, approx. 40,000 central labs all over the world will have the possibility to follow their own path regarding laboratory automation, and to develop new options regarding the certainty of results and productivity. The cell passage is a central labor-intensive routine step within the cell culture and, therefore, an ideal basis for the automated device solution For the first time, offers cell laboratories an affordable solution for the implementation already starting with small and medium passage numbers.

The production of cells and tissue for medical research and therapy is a promising future market. We are very satisfied that our cooperation as one of the worldwide leading suppliers is able to set important accents for bioproduction," says Dr. Soenke Brunswiek, Director Business Development at PharmaCell. "Automation plays an important role for success here, i.e. in particular safety and efficiency."

"Cooperation leads to innovation. The support of partnerships beyond national borders as in the example of InnoCyte and PharmaCell was the exact target of the Biomaterials Innovation Network Biomat-IN. We are therefore very pleased about this cooperation." commented Dr. Klaus Eichenberg, Managing Director of the BioRegio STERN Management GmbH.

About InnoCyte

InnoCyte GmbH is a technology specialist for innovative device solutions and automation all about cell culture with applications in the pharmaceutical and biotechnological industry as well as regenerative medicine. InnoCyte pursues a flexible and modular product strategy: Benchtop devices close the gap between labor-intensive and error-prone manual laboratory tasks and the expensive, complex robot systems. It is in this way that InnoCyte enables approximately 40,000 cell culture laboratories worldwide to choose their own path in laboratory automation and opens up new horizons for growth. InnoCyte is a spin-off of the Fraunhofer Gesellschaft.

About PharmaCell

PharmaCell is the leading European contract manufacturer (CMO) in the field of human cell therapy and regenerative medicine. PharmaCell has experience in supporting clinical phase I-III trials and commercialization projects regarding production, quality control (QC), quality testing (QT), batch certification, storage, and inbound and outbound logistics. The company offers contract services exclusively in the field of human cell therapy and regenerative medicine. Services include the process and assay development up to the GMP compliance as well as the guarantee of robust and scalable manufacturing processes. PharmaCell operates two state-of-the-art, cGMP-certified production plants in Maastricht, in the Netherlands, in the middle of Europe. The plants comprise 4,500 m2 including clean rooms of the classes A, B, C, and D (class 100/10,000/100,000), laboratories for research and development as well as quality control (QC), the cryoconservation, storage and logistic surfaces.

About Biomaterials Innovation Network Biomat-IN

The Biomaterials Innovation Network Biomat-IN includes five European BioRegions pooling their resources in an international network to support innovations in the field of biomaterials by way of transnational cooperation. Eurasanté and Atlanpole Biotherapies in France, BioRegio STERN Management GmbH in Germany, Medilink EM in Great Britain, and LIOF in the Netherlands. This progress in biotechnology, cell and tissue technique, and polymer chemistry requires the application of innovative biomaterials as well as new strategies for multidisciplinary research implemented by scientists and industrial partners.

InnoCyte GmbH, Nobelstr. 12, 70569 Stuttgart, Germany. Phone: +49 (0)711/970-1129, Fax: +49 (0)711/970-1005, Email:, Web:

PharmaCell B.V., Oxfordlaan 70, 6229 EV Maastricht, The Netherlands. Phone: +31 (0)43/35 09910, Fax: +31 (0)43/36 19732, E-mail:, Website:


Roland Huchler, +49 (0)176 200 601 06,
CEO and founder of InnoCyte GmbH

Record changed: 2017-04-02


Picture [iito] Plain Stupid Simple 650x80px

More documents for InnoCyte GmbH

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] No Content Marketing 650x80px

» top